- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04691700
GOREISAN for Heart Failure (GOREISAN-HF) Trial (GOREISAN-HF)
March 31, 2023 updated by: Takeshi Morimoto
The objective of the GOREISAN-HF trial is to assess the effect of the administration of Goreisan (TJ-17) plus standard therapy compared to standard therapy alone on the improvement rate of cardiac edema and clinical outcomes in worsening congestive heart failure with volume overload.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Current guidelines recommend the use of loop diuretics as an indication for class I to improve HF symptoms regardless of left ventricular ejection fraction.
Loop diuretics, however, are known to activate the renin-angiotensin-aldosterone system and the sympathetic nervous system, which could accelerate HF progression.
Loop diuretics could also cause worsening renal function and electrolyte disturbance, and it is desirable to have an alternative drug to loop diuretics to effectively relieve congestive symptoms.
Goreisan (TJ-17), a traditional Japanese medicine composed of five herbal medicines, has long been used in Japan to treat impairments of the regulation of body fluid homeostasis, including edema, and has been less likely to cause renal dysfunction and electrolyte abnormalities.
We therefore planned a multicenter, randomized, interventional, parallel assignment, open-label treatment trial to evaluate the long-term effect of in-hospital initiation of Goreisan, when added to standard therapy, in patients with worsening congestive heart failure and clear signs of volume overload.
Study Type
Interventional
Enrollment (Anticipated)
2192
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hidenori Yaku, MD, PhD
- Phone Number: +81-75-751-4255
- Email: yakuh@kuhp.kyoto-u.ac.jp
Study Locations
-
-
-
Kyoto, Japan, 606-8507
- Recruiting
- Kyoto University Graduate School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Confirmed congestive heart failure (CHF) by Framingham criteria
- CHF patients with cardiac edema and signs due to cardiac edema (signs of fluid overload: lower limb edema, pulmonary effusion, or pulmonary congestion on chest x-ray)
- Elevated N-terminal pro brain-type natriuretic peptide (NT-proBNP) ≥300 pg/mL or brain natriuretic peptide (BNP) ≥100 pg/mL at enrollment
- Patients ≥ 20 years of age, male or female
- Provision of signed informed consent before any assessment is performed
Exclusion Criteria:
- Valvular repair/replacement within 12 weeks prior to enrolment or planned to undergo any of these operations after randomization
- Implantation of a cardiac resynchronization therapy (CRT) within 12 weeks prior to enrollment or intent to implant a CRT device
- Previous cardiac transplantation or implantation of a ventricular assistance device or similar device, or implantation expected after randomization
- End-stage renal failure (estimated glomerular filtration rate [eGFR] <15 mL/min/1.73m2) at enrollment
- Patients who are expected to have a life expectancy of 6 months or less
- Acute coronary syndrome at screening
- Women of child-bearing potential or women who have a positive pregnancy test at enrolment or randomization
- Treatment with herbal medicine at enrollment
- Confirmed poor tolerability of Goreisan (including cinnamon allergy)
- Considered not appropriate for the participation of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Goreisan
Goreisan (TJ-17) will be added at a dose of 7.5g per day to standard treatment
|
Add Goreisan 7.5g per day to standard treatment with the intention to reduce or discontinue the existing diuretics
|
Active Comparator: No Goreisan
Standard treatment without Goreisan (TJ-17)
|
Standard therapy without Goreisan
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement of cardiac edema
Time Frame: 1 year
|
Cardiac edema is defined as conditions having one or more following conditions: lower limb edema, pleural effusion, or pulmonary congestion on chest x-ray.
Lower limb edema, pleural effusion, and pulmonary congestion are assessed by investigators.
Improvement is defined as the disappearance of all signs of cardiac edema.
|
1 year
|
Composite endpoint of all-cause death or hospitalization
Time Frame: 3 years
|
Composite of death from any cause or hospitalization from any cause.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score
Time Frame: 6 months
|
The KCCQ is a validated self-administered instrument of quality of life and health status in heart failure (HF) patients.
The clinical summary score is a composite assessment of physical limitation, total symptom score, health-related quality of life, and social limitation scores.
Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
|
6 months
|
Change in loop diuretics dose
Time Frame: 6 months
|
Loop diuretic dose will be calculated as furosemide-equivalent dose.
|
6 months
|
Change in loop diuretics dose
Time Frame: 1 year
|
Loop diuretic dose will be calculated as furosemide-equivalent dose.
|
1 year
|
Composite endpoint of sustained decline in eGFR ≥50%, ESRD (end stage renal disease) or renal death
Time Frame: 3 years
|
End Stage Renal Disease (ESRD) is defined as: Sustained eGFR <15 mL/min/1.73m2,
Chronic dialysis treatment or, receiving a renal transplant.
Renal death is defined as renal failure as the underlying cause of death.
|
3 years
|
Adverse drug event
Time Frame: 3 years
|
Adverse drug event is an injury resulting from medical intervention related to any drug.
|
3 years
|
Change in a composite congestion score
Time Frame: 1 month
|
Dyspnea, fatigue, orthopnea, jugular vein distention, rales, plueral effusion, and lower limb edema are assessed on a standardized 4-point scale ranging from 0 to 3. A composite congestion score is calculated by summing the individual scores for dyspnea, fatigue, orthopnea, jugular vein distention, rales, plueral effusion, and lower limb edema.
|
1 month
|
Change in a composite congestion score
Time Frame: 6 months
|
Dyspnea, fatigue, orthopnea, jugular vein distention, rales, plueral effusion, and lower limb edema are assessed on a standardized 4-point scale ranging from 0 to 3. A composite congestion score is calculated by summing the individual scores for dyspnea, fatigue, orthopnea, jugular vein distention, rales, plueral effusion, and lower limb edema.
|
6 months
|
Change in a composite congestion score
Time Frame: 1 year
|
Dyspnea, fatigue, orthopnea, jugular vein distention, rales, plueral effusion, and lower limb edema are assessed on a standardized 4-point scale ranging from 0 to 3. A composite congestion score is calculated by summing the individual scores for dyspnea, fatigue, orthopnea, jugular vein distention, rales, plueral effusion, and lower limb edema.
|
1 year
|
All-cause hospitalization
Time Frame: 3 years
|
Hospitalization from any cause.
|
3 years
|
Composite endpoint of all-cause death or hospitalization for heart failure
Time Frame: 3 years
|
Composite of death from any cause or hospitalization for heart failure.
|
3 years
|
Hospitalization for heart failure
Time Frame: 3 years
|
Hospitalization for heart failure.
|
3 years
|
All-cause death
Time Frame: 3 years
|
Death from any cause.
|
3 years
|
Non-cardiovascular death
Time Frame: 3 years
|
Death other than death from cardiac or vascular diseases.
|
3 years
|
Change in New York Heart Association (NYHA) functional class
Time Frame: 6 months
|
Change in New York Heart Association (NYHA) functional class, a well established grading scale to classify a patients' level of functionality based on the signs and symptoms of patient with heart failure.
|
6 months
|
Change in N-terminal pro brain-type natriuretic peptide (NT-proBNP)
Time Frame: 1 month
|
Change in N-terminal pro brain-type natriuretic peptide (NT-proBNP).
|
1 month
|
Change in N-terminal pro brain-type natriuretic peptide (NT-proBNP)
Time Frame: 6 month
|
Change in N-terminal pro brain-type natriuretic peptide (NT-proBNP).
|
6 month
|
Change in N-terminal pro brain-type natriuretic peptide (NT-proBNP)
Time Frame: 1 year
|
Change in N-terminal pro brain-type natriuretic peptide (NT-proBNP).
|
1 year
|
Direct healthcare cost
Time Frame: 1 year
|
Direct healthcare cost (Japanese Yen) from the time of randomization to 12 months was obained from the claim data patients.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Takeshi Kimura, MD, PhD, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 19, 2021
Primary Completion (Anticipated)
January 1, 2024
Study Completion (Anticipated)
March 1, 2026
Study Registration Dates
First Submitted
December 20, 2020
First Submitted That Met QC Criteria
December 30, 2020
First Posted (Actual)
December 31, 2020
Study Record Updates
Last Update Posted (Actual)
April 3, 2023
Last Update Submitted That Met QC Criteria
March 31, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Y0075
- jRCT (Registry Identifier: jRCT2071220069)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted